iQSTEL's Preliminary Q3 Revenue Shows Growth but No Profitability or Ultranet Close

What happened

iQSTEL reported preliminary Q3 2026 revenue of $106 million, down 2.8% sequentially from Q2's $109.1 million, and nine-month revenue of $314 million, up 35% year-over-year organically. The company reiterated its $430 million full-year 2026 revenue target and noted the proposed Ultranet acquisition would add roughly $131 million in annual revenue, but management gave no update on when or if that deal will close. The top-line growth is real, yet it masks persistent structural weakness: Q1 2026 gross margin was only about 2.1%, operating losses continued, and cash flow remained negative, with management previously warning of substantial doubt about its ability to continue as a going concern. With Q3 revenue now below Q2, there is early evidence that organic growth is decelerating, making the company's reliance on the Ultranet deal and dilutive equity financing more pronounced. The press release highlights the favorable revenue picture while omitting any profitability, cash flow, or liquidity metrics, which is a selective disclosure that investors should treat with skepticism.

Implication

The preliminary results give management a chance to reinforce the growth narrative, but without audited profitability or cash flow data, the news does not address the core concerns that drove the WAIT rating: thin gross margins, operating losses, and going-concern language. Sequential revenue decline from Q2 to Q3 suggests organic momentum may be fading, which increases dependence on the Ultranet acquisition to sustain top-line growth, yet the deal remains unclosed as of this announcement. If the upcoming 10-Q shows continued negative operating cash flow and the same 'substantial doubt' disclosure, the equity line at 94% of lowest VWAP will likely become the primary funding source, accelerating dilution for current shareholders. Investors should also monitor whether the company has executed any of the authorized buyback, since doing so while relying on discounted equity issuance would be a clear sign of poor capital allocation discipline. Until a definitive Ultranet agreement is filed and consolidated profitability improves, the stock's risk/reward remains unattractive, with downside to the bear-case $0.70 implied value more likely than upside to the bull-case $1.90.

Thesis delta

The thesis weakens slightly because the key catalyst, a definitive Ultranet agreement by early August 2026, has not materialized as of this announcement, and organic revenue growth is plateauing sequentially. However, the revenue scale is still intact, so the base-case WAIT remains, but the balance of risks shifts toward the bear scenario if Q3 10-Q confirms continued losses and dilution.